Miscellaneous Malignancies | Norton Healthcare

Indication: Miscellaneous Malignancies

A Phase 1b/2 Open-Label Study Evaluating Tazemetostat In Combination With Enzalutamide Or Abiraterone/Prednisone In Chemotherapy Naive Subjects With Metastatic Castration Resistant Prostate Cancer

Advanced Malignancies

Sub-indication: Metastatic Castration Resistant Prostate Cancer

Line of Therapy: relapsed/refractory

Drug Study

Principal Investigator: Jaspreet Grewal, M.D.
Norton Cancer Institute

Sponsor: Epizyme, Inc

Learn more at ClinicalTrials.gov

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.